• Summit Therapeutics published a presentation on HARMONi-GI1, a randomized, double-blind Phase 3 trial in advanced biliary tract cancer.
• Ivonescimab with chemotherapy significantly improved overall and progression-free survival versus durvalumab with chemotherapy as first-line treatment for advanced biliary tract cancer.
• Objective response rates also improved significantly in the preplanned interim analysis of the China-based trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.